The relapsed or refractory diffuse large B-cell lymphoma market has witnessed significant growth over the past few years owing to the increasing prevalence of lymphoma across the globe. Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that affects B-cells and accounts for around 30% of newly diagnosed cases of non-Hodgkin lymphoma. Despite advances in upfront treatment options like combination chemoimmunotherapy, up to 40% of patients experience relapse or become refractory. Treatment of relapsed/refractory DLBCL aims to control tumor growth, reduce symptoms, improve quality of life, and potentially cure the disease. The key therapies for relapsed and refractory DLBCL include CAR T-cell therapy, monoclonal antibodies, and chemotherapy. The Global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the relapsed or refractory diffuse large B-cell lymphoma are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. These key players are focusing on developing innovative and better treatment options for relapsed/refractory DLBCL patients. For instance, in 2021, LG Corporation launched a chimeric antigen receptor T-cell therapy drug for the treatment of relapsed/refractory DLBCL.
There is significant opportunity in the market related to the development of combination therapies. The combination of CAR T-cell therapy, monoclonal antibodies and other therapies is expected to provide better outcomes for relapsed/refractory patients. For example, the combination of anti-CD19 CAR T-cell therapy with monoclonal antibodies like rituximab or obinutuzumab.
The major players are expanding globally to increase their market share in the high growth regional markets. For instance, in 2022, Hitachi expanded its operations in Latin America by acquiring a Brazilian medical device company to strengthen its position in the relapsed/refractory oncology market.
Market drivers
The increasing prevalence of lymphoma is a major driver of the Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Trends According to the estimates of Lymphoma Research Foundation, around 74,200 people will be diagnosed with some form of non-Hodgkin lymphoma in 2021 in the US. Further, technological advancements leading to development of novel targeted therapies like CAR T-cell therapy and monoclonal antibodies are expected to drive the market growth during the forecast period.
Market restraints
High cost of the targeted therapies like CAR T-cell therapy remains one of the major challenges in the market. The total cost of CAR T-cell therapy can range from $250,000 to $400,000 per patient in the US. Further, complex manufacturing process of cell and gene therapy products also adds to their overall cost. This high cost restrains the adoption of these novel therapies, especially in low and middle-income countries.
Segment Analysis
The relapsed or refractory diffuse large B-cell lymphoma market can be segmented based on treatment type and geography. Based on treatment type, the market can be classified into monoclonal antibodies, chemotherapy, targeted therapy, and others. Among these, the monoclonal antibodies segment dominated the market in 2024 owing to the increased adoption of antibodies like Rituximab and Brentuximab for treating relapsed/refractory DLBCL. Monoclonal antibodies provide durable long-term benefits to patients and have better survival outcomes than conventional chemotherapy treatments.
Global Analysis
Regionally, North America dominated the relapsed or refractory diffuse large B-cell lymphoma market in 2024 and is expected to continue its dominance during the forecast period. This is owing to the developed healthcare infrastructure, high treatment cost, and presence of key players in the region. However, Asia Pacific is anticipated to witness the highest growth rate during 2024-2030 due to large patient population, increasing incidence of lymphoma, rising healthcare expenditure, and improving healthcare facilities in emerging countries such as China and India. The key players globally are focusing on launching innovative treatment therapies and undertaking partnerships and agreements to strengthen their market position and expand presence across different regions.
Get more insights, On Relapsed or Refractory Diffuse Large B-cell Lymphoma Market
Comments
0 comment